The small molecule phosphoinositide 3-kinase delta inhibitor, which is now the first ever APDS treatment to be licensed for use in the NHS in England, has been indicated for use in adults and adolescents aged 12 years and older.
Approximately 40 to 50 people in the UK are known to be living with APDS, an inherited disorder that affects how the body’s immune system works, meaning patients have a reduced ability to fight infections…
